Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:46:33 EDT Sat 18 May 2024
Enter Symbol
or Name
USA
CA



News for U:XOMA from 2023-05-18 to 2024-05-17 - 25 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-14 07:30U:XOMANews ReleaseXOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
2024-05-09 07:30U:XOMANews ReleaseXOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
2024-04-30 07:30U:XOMANews ReleaseXOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO(TM) (clindamycin phosphate) Vaginal Gel 2%
2024-04-25 07:30U:XOMANews ReleaseXOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
2024-04-24 09:00U:XOMANews ReleaseActym Therapeutics Appoints Thomas Smart as CEO
2024-04-03 09:00U:XOMANews ReleaseXOMA Corporation Announces Closing of Tender Offer
2024-03-21 07:30U:XOMANews ReleaseXOMA Declares Quarterly Preferred Stock Dividends
2024-03-19 16:05U:XOMANews ReleaseXOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
2024-03-08 07:30U:XOMANews ReleaseXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
2024-02-28 07:30U:XOMANews ReleaseXOMA to Present at Upcoming Investor Conferences in March
2024-02-16 08:00U:XOMANews ReleaseXOMA Enters into Agreement to Acquire Kinnate Biopharma ‚  for Between $2.3352 and $2.5879 in Cash Per Share ‚  Plus a Contingent Value Right
2024-01-18 08:30U:XOMANews ReleaseXOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA ‚ ® Acquisition
2024-01-11 16:05U:XOMANews ReleaseFDA Acceptance of Zevra ¢ € ™s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
2024-01-08 07:30U:XOMANews ReleaseXOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
2024-01-02 07:30U:XOMANews ReleaseXOMA Announces Stock Repurchase Program of up to $50 Million
2023-12-20 07:30U:XOMANews ReleaseXOMA Declares Quarterly Preferred Stock Dividends
2023-12-19 07:30U:XOMANews ReleaseXOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing ‚  from Funds Managed by Blue Owl Capital Backed by VABYSMO ‚ ® Royalties
2023-11-07 07:30U:XOMANews ReleaseXOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
2023-10-31 07:30U:XOMANews ReleaseXOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One ¢ € ™s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
2023-09-25 07:30U:XOMANews ReleaseXOMA Declares Quarterly Preferred Stock Dividends
2023-09-06 07:30U:XOMANews ReleaseXOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference
2023-08-08 07:30U:XOMANews ReleaseXOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy
2023-06-23 18:15U:XOMANews ReleaseXOMA Added to the Russell 2000 ‚ ® and Russell 3000 ‚ ® Indexes
2023-06-22 07:30U:XOMANews ReleaseXOMA Acquires Royalty and Milestone Economics to ‚  Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) ‚  and Phase 2 Oncology Asset
2023-06-20 07:30U:XOMANews ReleaseXOMA Declares Quarterly Preferred Stock Dividends